Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Regeneron Pharmaceuticals and Sanofi have launched an open-label, expanded access program titled ‘Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid.’ The study aims to provide dupilumab treatment to patients with Bullous Pemphigoid who participated in a previous phase 2/3 study, focusing on evaluating the long-term safety of the drug. This program is significant as it offers continued treatment options for patients with this rare skin condition.
The intervention being tested is dupilumab, administered subcutaneously. Dupilumab is a drug designed to treat inflammatory conditions, and in this context, it is intended to manage Bullous Pemphigoid symptoms.
The study is designed as an expanded access program, meaning it is not a traditional clinical trial but rather a means to provide treatment to patients who need it. There is no random allocation or masking involved, and the primary purpose is treatment.
The study was first submitted on June 7, 2023, with the latest update expected by June 30, 2025. These dates are crucial as they mark the timeline for the study’s progression and updates on its findings.
The market implications of this study update could be significant for Regeneron Pharmaceuticals and Sanofi. Positive outcomes could enhance investor confidence and potentially boost stock performance, especially given the competitive landscape in the pharmaceutical industry where innovative treatments are highly valued.
The study is ongoing, with further details available on the ClinicalTrials portal.